TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04551066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib will be administered QD orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: ruxolitinib will be administered BID orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ruxolitinib
Description: ruxolitinib will be administered BID orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be administered QD orally
Study: NCT06326489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Switching to the Medtronic 780G insulin pump
Description: Patients using a Medtronic 740G insulin pump will receive the 780G model for three months
Study: NCT05191979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise regiment (aerobic exercise on bike)
Description: Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise regiment (aerobic exercise on bike)
Description: Subjects participating in the current study will be trained progressively and intensively for 12 months primarily on bike indoors and outdoors
Study: NCT06047171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALE.F02
Description: ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALE.F02
Description: ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALE.F02
Description: ALE.F02 is an anti-Claudin-1 (CLDN1) monoclonal antibody (mAb) to selectively target the non-tight junctions (TJ), exposed form of CLDN1. CLDN1 is an integral component of the TJs between cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a monoclonal antibody that targets cluster of differentiation antigen 20 (CD20), an antigen expressed on the surface of pre-B and mature B-lymphocytes
Study: NCT01430429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NI-0801
Study: NCT05320627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Eligible patients will receive Edoxaban tablet once a day for 12 weeks
Study: NCT05054244

Intervention type: OTHER
Intervention: standard wound treatment
Description: Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).

Intervention type: OTHER
Intervention: standard wound treatment
Description: Standard treatment includes dressings, debridement, antibiotics, and bacterial load relief. The dressing will be performed according to wound characteristics with change every two days including primary dressing (alginates, hydrofiber dressing, antimicrobial dressing, gelling fiber dressing), with silver if infected, and secondary protective dressing (foam with polyurethane) in wounds with formed granulation tissue. The progression of the wound and the need for specific treatment will be evaluated weekly by dermatologist and vascular surgeon specializing in wound care, and appropriate treatment conducted according to wound assessment (antibiotics, bandage, dressing change, debridement, amputations).

Intervention type: PROCEDURE
Intervention: Hyperbaric oxygenation (HBOT)
Description: The HBOT sessions will be performed 5 days a week, in multi-place chamber at 2.4 atm absolute (ATA) and 100% O2 with effective treatment lasting for 90 min. The sessions will be supervised by doctors trained in hyperbaric medicine.
Study: NCT05523518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Buzzy®
Description: From one minute before the location of the catheter and until the end of the procedure, the researchers will place the Buzzy® device approximately 5cm above the area where the procedure will take place, with its wings under it. The gel in its wings will have been previously frozen solid in a refrigerator. In this way, vibration and cold will be applied, and immediately afterwards, vein entry will be performed. (For the children's safety, a piece of thin sterile gauze will be placed on the area in order to prevent direct contact between the ice wings and the skin.)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The AccuVein®
Description: In this group, the veins in the area where the entry is to be performed will be visualized with the AccuVein® infrared vein visualization device, and the standard catheter implementation will be performed in the vein which is decided on for entry.
Study: NCT04146298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered prior to cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered prior to cell infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mutant KRAS G12V-specific TCR transduced autologous T cells
Description: After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.
Study: NCT05322590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). BXQ-350 will be administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be 0.9% normal saline of matching volume to BXQ-350 administered by intravenous (IV) infusion over six months and continued for an additional 20 months for participants who remain eligible (Stage 2 only)
Study: NCT05815784

Intervention type: DEVICE
Group type: OTHER
Intervention: MiSight contact lenses
Description: Daily wear for 2 years.
Study: NCT05269940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: oral dosing, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: oral dosing, once daily
Study: NCT06661915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study: NCT06024330

Intervention type: DIAGNOSTIC_TEST
Intervention: VAN assessment
Description: An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.

Intervention type: DIAGNOSTIC_TEST
Intervention: VAN assessment
Description: An investigator assesses the VAN scale when a patient arrives at ED triage with a suspected stroke.

Intervention type: DIAGNOSTIC_TEST
Intervention: VES assessment
Description: An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.

Intervention type: DIAGNOSTIC_TEST
Intervention: VES assessment
Description: An investigator assesses the VES scale when a patient arrives at ED triage with a suspected stroke.

Intervention type: DIAGNOSTIC_TEST
Intervention: LARIO assessment
Description: An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.

Intervention type: DIAGNOSTIC_TEST
Intervention: LARIO assessment
Description: An investigator assesses the LARIO scale when a patient arrives at ED triage with a suspected stroke.
Study: NCT06661915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iadademstat
Description: Given PO
Study: NCT06672237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nexiguran ziclumeran
Description: nexiguran ziclumeran 55 mg by single IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline as Placebo
Description: Normal saline (0.9% NaCl) by single IV infusion
Study: NCT06442774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: The intervention that has been developed is a digital tool of a biopsychosocial nature based on the main cognitive-behavioral strategies: psychoeducation, reflection, self-observation, guided visualizations, mindfulness and progressive muscle relaxation.~The intervention consists of 3 main areas of work:~* Programs: Biopsychosocial programs in text and audio format.~* Community: Forum with directed questions and space to share experiences between mothers.~* Diary: Space to record mood and emotional record.~The entire tool works transversally in 4 dimensions: self-care, relationship with perinatal changes, relationship with the baby, social relationship.~The tool itself includes 3 mental health and well-being screening questionnaires: Whooley Questionnaire and the Edinburgh Postnatal Depression Scale (EPDS).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring via wearable
Description: Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring via wearable
Description: Participants that own a wearable will connect it to monitor variables related to sleeping patterns, activity and stress (see variables section).
Study: NCT06361745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T cell injection targeting CD19 chimeric antigen receptor
Description: Intravenous administration, 1 bag each time (depending on individual differences), dose: 1×108-1×109 CD19-CAR-gdT (UTAA09 injection), the investigator can decide whether to reduce or increase the dose and whether multiple infusions are required according to the condition of the subject.
Study: NCT06617793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rapcabtagene autoleucel (YTB323)
Description: CAR-T cell suspension for intravenous infusion
Study: NCT05280613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up
Description: See arm/group description

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: See arm/group description
Study: NCT06617715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sinovac PCV13
Description: One dose of Sinovac PCV13 (0.5 mL) is administered intramuscularly.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®
Description: One dose of Prevnar® (0.5 mL) is administered intramuscularly.
Study: NCT06411379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonelokimab
Description: Sonelokimab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04461509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA
Description: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-PSMA
Description: Imaging (comparing standard and experimental high resolution diffusion-weighted imaging \[DWI\] MRI with 18F-PSMA)~Other Names:~18F-DCFPyL Injection prostate-cancer-specific radiotracer
Study: NCT06681077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Community Health Education
Description: Receive I CAN intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05138848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time in Bed Restriction
Description: Participants will undergo a 4-week sleep intervention that includes specified in- and out-of-bed times as well as a restriction to their habitual time in bed (average sleep opportunity including naps). This will be truncated equally at the beginning and end of the night.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Schedule
Description: Participants will maintain their typical sleep schedule for 4-weeks.
Study: NCT05269940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX-101A
Description: oral dosing, once daily
Study: NCT05649124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure group
Description: A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points open. The most preferred points LI4, SP6 and ST36 were selected among the points that were reported to be effective in relieving luterus pain by scanning the literature on the points to be compressed. Acupressure will be applied to the points (bidirectional, right and left) for 2 minutes, for a total of 8 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it is passed to the other point in the symmetrical region and the application is made without interruption. While practicing, the researcher will check the time using a digital wristwatch with a stopwatch.
Study: NCT05138848

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Schedule
Description: Participants will maintain their typical sleep schedule for 4-weeks.
Study: NCT06618417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sleep apnea home-evaluation
Description: Participants will receive a home-monitoring device by mail to test for sleep apnea at home
Study: NCT06676189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with medial pivot polyethylene
Description: total knee arthroplasty with medial pivot polyethylene

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with ultra-congruent polyethylene
Description: total knee arthroplasty with ultra-congruent polyethylene
Study: NCT06623331

Intervention type: OTHER
Intervention: AI-enhanced endoscopy training
Description: Endoscopists trained in AI-enhanced environment. Their quality indicators are measured after completing training, without additional AI enhancement.

Intervention type: OTHER
Intervention: Conventional endoscopy training
Description: Endoscopists trained conventionally
Study: NCT06696118

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Transduction Therapy (EMTT)
Description: Subjects will be treated with Electromagnetic Transduction Therapy (EMTT) using the Curamedix MAGNETOLITH device. Treatments will be administered twice per week, for four weeks. Each treatment will have the following settings: level 8, 8Hz, and 10,000 pulses andwill take about 15 to 20 minutes. Treatments will be spaced 2-3 days apart.
Study: NCT06696391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous Excess Ultrasound (VEXUS)-Guided Management
Description: Expert operators will perform VEXUS within 6 hours of randomization and repeat the assessment every 24 hours for 3 days, or until ICU discharge or death. After each assessment, investigators will grade the severity of venous congestion using a modified version of the VEXUS score and provide updated management recommendations.~Patients without congestion will receive standard fluid management. For mild congestion, investigators will implement fluid restriction (e.g., minimizing maintenance fluids) while maintaining nutrition and blood product administration as clinically indicated. For moderate to severe congestion, investigators will 1. target negative fluid balance (-1 to -2L/24h) through fluid restriction and diuretics, 2. perform cardiac ultrasound to guide inotrope administration and optimize RV physiology, and 3. optimize PEEP for ventilated patients.~All patients will receive the standard of care based on Surviving Sepsis Campaign guidelines.
Study: NCT06719089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable double loop ureteral stent
Description: This ureteral stent is based on natural polymers and degrades inside the human body without causing obstruction, avoiding the need of a second surgery for stent removal and minimizing complications related to encrustation and bacterial infections.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PolyUrethane Double Loop Ureteral Stent
Description: This ureteral stent is a double J made of 100% polyurethan, heat-sensitive and radiopaque for excellent patient tolerance and high incrustation resistance.
Study: NCT06779955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: foot massage application
Description: The characteristics of Massage Manipulations are an important feature in planning. Since the purpose of the massage is to rest, calm and relax, Effleurage (Stroke), Petrisage (Kneading) and Friction (Circular Rubbing) techniques that support circulation and have a loosening effect on the tissues have been chosen.A massage will be given to both feet for a total of 16 minutes, 8 minutes for each foot.The person receiving the massage will be lying down comfortably in a supine position, supported by pillows under the head and lower legs.Foot massage will be applied once to patients in the supine position at the first hour after their admission to the coronary intensive care unit following transfemoral angiography.
Study: NCT06781268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Kinetic Training
Description: Combination of cognitive and physical exercises aimed at improving neuroplasticity, agility, balance, and cognitive functions.
Study: NCT06780657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online hypopressive exercise training program
Description: The hypopressive exercises were based on recommendations from the literature and consultation with an expert in the field. Each session will be held twice a week for 20-25 minutes. Participants will perform each exercise 10 times during these sessions.
Study: NCT06780748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Identification rate of sentinel lymph node
Description: To evaluate the identification rate of sentinel lymph nodes (SLNs). The study will compare the identification rates based on different localization techniques for SLN mapping
Study: NCT06780241

Intervention type: DIAGNOSTIC_TEST
Intervention: CMR
Description: CMR (with contrast at baseline and non-contrast at follow-up)

Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Rapid Assessment of Physical Activity questionnaire and the Kansas City Cardiomyopathy Questionnaire
Study: NCT06780449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Participants will receive cagrilintide subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive semaglutide subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cagrilintide
Description: Participants will receive placebo matched to cagrilintide subcutaneously.
Study: NCT06338059

Intervention type: OTHER
Intervention: Vitamin B12 Level
Description: Vitamin B12 Level Laboratory measurement of patient's vitamin B12 level in unit of pg/mL 25 OH Vitamin D Level Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl

Intervention type: OTHER
Intervention: Vitamin B12 Level
Description: Vitamin B12 Level Laboratory measurement of patient's vitamin B12 level in unit of pg/mL 25 OH Vitamin D Level Laboratory measurement of patient's 25 OH vitamin D level in unit of ng/dl
Study: NCT06780449

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo semaglutide
Description: Participants will receive placebo matched to semaglutide subcutaneously.
Study: NCT06781060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Faradic Nerve Stimulation Therapy+Standard Physiotherapy
Description: This is electrical nerve stimulation with faradic type current to the injured nerve for conservative treatment of post injection sciatic nerve injury.